Amarin_Logo_JPEG.jpg
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
January 25, 2021 19:35 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA® (icosapent ethyl)...
Amarin_Logo_JPEG.jpg
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
January 21, 2021 16:30 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent...
Amarin_Logo_JPEG.jpg
Amarin Provides Preliminary 2020 Results and 2021 Outlook
January 07, 2021 06:05 ET | Amarin Corporation plc
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European Regulatory Review and Submission of China...
Amarin_Logo_JPEG.jpg
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 06:05 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is...
Amarin_Logo_JPEG.jpg
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
December 14, 2020 05:00 ET | Amarin Corporation plc
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA...
Amarin_Logo_JPEG.jpg
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
December 12, 2020 21:30 ET | Amarin Corporation plc
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity...
Amarin_Logo_JPEG.jpg
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020
December 07, 2020 07:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that scientific findings that add to the growing body of knowledge on...
Amarin_Logo_JPEG.jpg
Amarin Files Patent Infringement Lawsuit Against Hikma
November 30, 2020 19:55 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a...
Amarin_Logo_JPEG.jpg
Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)
November 24, 2020 06:05 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is...
Amarin_Logo_JPEG.jpg
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
November 19, 2020 18:30 ET | Amarin Corporation plc
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol (LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose...